Zai Lab Executive and Leadership Team

Xiaoxi Wang, the Deputy Chief Financial Officer at Zai Lab, directs financial operations and fiscal strategy. Overseeing accounting, budgeting, and financial reporting, Wang ensures robust financial health for the bio-pharmaceutical company. This leadership position involves managing capital allocation and supporting Zai Lab's drug discovery and development initiatives in oncology and autoimmune diseases. Wang's oversight extends to financial compliance and risk management, safeguarding the company's assets and investments. The role requires close collaboration with other finance leaders to optimize financial performance and support strategic growth objectives. By maintaining stringent financial controls, Xiaoxi Wang contributes directly to Zai Lab's mission of bringing innovative treatments to patients worldwide.

Kari Lee, the Deputy Chief Financial Officer at Zai Lab, manages critical financial planning and analysis functions. Lee's responsibilities encompass developing financial models, forecasting future performance, and providing insights to support Zai Lab's strategic decisions in oncology and autoimmune disease research. This role involves close coordination with the Chief Financial Officer and other executive team members to ensure financial resources are effectively deployed for drug discovery and commercialization efforts. Lee also plays a part in investor relations, communicating financial performance and outlook to stakeholders. The Deputy Chief Financial Officer's work is essential for maintaining Zai Lab's financial stability and enabling its expansion into new therapeutic areas. Kari Lee's expertise drives financial discipline across the organization.

Diana Liu, the Deputy Chief Financial Officer at Zai Lab, oversees treasury operations and corporate finance initiatives. Liu manages cash flow, debt financing, and investment strategies, ensuring Zai Lab has the necessary capital to fund its extensive bio-pharmaceutical research and development pipeline. This position involves optimizing the company's capital structure and managing relationships with financial institutions. Liu's contributions are vital for supporting Zai Lab's focus on oncology and autoimmune diseases, facilitating the progression of drug candidates through clinical trials and towards market approval. The Deputy Chief Financial Officer's strategic financial management underpins the company's growth and its commitment to delivering life-changing therapies. Diana Liu ensures financial resilience for Zai Lab's global operations.

William Liang, the Chief Commercial Officer & President, Greater (China) at Zai Lab, spearheads commercialization strategies and market access initiatives. Liang directs sales, marketing, and business development efforts, focusing on bringing Zai Lab's innovative oncology and autoimmune disease treatments to patients within China and the broader Greater China region. This executive role involves building and leading high-performing commercial teams, establishing key partnerships, and ensuring robust market penetration for the company's approved therapies. William Liang's leadership is critical for translating Zai Lab's drug discovery successes into tangible commercial outcomes and patient impact. The Chief Commercial Officer & President, Greater (China) ensures strategic alignment between product development and market needs, driving revenue growth and expanding Zai Lab's footprint in key Asian markets.

Harald Reinhart, the Chief Medical Officer at Zai Lab, directs all clinical development and medical affairs strategies. Reinhart oversees the design and execution of clinical trials for Zai Lab's oncology and autoimmune disease drug candidates, ensuring adherence to global regulatory standards and scientific rigor. This leadership role involves guiding the medical team in evaluating drug efficacy and safety, and translating scientific findings into viable therapeutic solutions. Reinhart collaborates closely with research and development teams to advance the company's pipeline from preclinical stages through to regulatory submission. The Chief Medical Officer's expertise is crucial for navigating the complexities of drug development and positioning Zai Lab's innovations for maximum patient benefit. Harald Reinhart drives the medical vision for Zai Lab's therapeutic advancements.